Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)
- People whose cancer continued to grow or spread while being treated with a type of cancer treatment called immunotherapy (also known as immune checkpoint inhibitors, or ICI)
- People who are willing and able to sign a written consent form agreeing to take part in the study
- People who are 18 years of age or older at the time of signing the consent form
Who may not be able to join:
- People who are under legal guardianship or a form of court-appointed legal protection (confirm with trial site)
- People who are unable to sign or give written consent to participate in the study
- People for whom it is not technically possible to have a tissue sample (biopsy) taken from their tumour using local anaesthetic
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Etienne Giroux Leprieur, MD, PhD, Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
Phone: +33 1 49 09 58 02
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of specific histomolecular resistance
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.